Expertise in
1
conditions

Wen F. Tang

Sir Run Run Shaw Hospital Of Zhejiang University School Of Medicine
Hangzhou, CN 
Expertise in
1
conditions
Sir Run Run Shaw Hospital Of Zhejiang University School Of Medicine
Hangzhou, CN 
OverviewLocationsClinical Research

Overview

Wen Tang practices in Hangzhou, China. Tang is highly rated in 1 condition, according to our data. Their top areas of expertise are Triple-Negative Breast Cancer, Kimura Disease, Tenesmus, Colonoscopy, and Endoscopy.

Their clinical research consists of co-authoring 102 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years.

Locations

Sir Run Run Shaw Hospital of Zhejiang University School of Medicine
Hangzhou, China
Other Locations
1055 Sanxiang Road, Suzhou, China
State Key Laboratory Of Bioreactor Engineering, Shanghai, 200237, China
No. 521 Xingnan Road, Guangzhou, 511400, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3, Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients With Crohn's Disease
A Phase 3, Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients With Crohn's Disease
Enrollment Status: Active_not_recruiting
Publish Date: April 18, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
Enrollment Status: Completed
Publish Date: December 27, 2024
Intervention Type: Drug
Study Drugs: Mirikizumab, Ustekinumab
Study Phase: Phase 3
View 1 Less Clinical Trial

102 Total Publications

Analysis of differential expression of blood RNA in children with Juvenile idiopathic arthritis treated with TNF antagonists
Analysis of differential expression of blood RNA in children with Juvenile idiopathic arthritis treated with TNF antagonists
Journal: Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
Published: October 10, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Tang's expertise for a condition
ConditionClose
      View All 26 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile